Firms battle over Merck

Williams, Dede
February 2007
ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p9
Trade Publication
The article focuses on the companies bidding for Merck Generics. India's Ranbaxy is bidding for Merck together with Kohlberg, Kravits, Roberts. Actavis has confirmed that it is interested in buying Merck. Other bidders include Texas Pacific, Bain Capital, Blackstone, Permira and EQT. Merck KGaA is selling Merck Generics to help finance its Serono buy.


Related Articles

  • Merck generics sale to create powerhouse? Mirasol, Feliza // ICIS Chemical Business Americas;1/15/2007, Vol. 271 Issue 2, p24 

    The article reports on the plan of Merck KGaA to sell its generics business. The generics business of the company ranks among the leading generics operations worldwide. Its rivals include major players Teva, Novaris and Barr Pharmaceuticals. The leading contender for the business is Ranbaxy, the...

  • Mylan buys Merck's generics division.  // TCE: The Chemical Engineer;Jun2007, Issue 792, p5 

    The article reports on the acquisition of the generic pharmaceuticals division of Merck KGaA by Mylan Laboratories for €4.9 billion. Other companies that bided for the division include Teva Pharmaceuticals and Actavis. It notes that the generic division had sales of €1.8 billion in...

  • Full steam ahead for Actavis in generics.  // Chemical Market Reporter;7/17/2006, Vol. 270 Issue 2, p24 

    The article announces that Iceland-based Actavis is pushing through with its generic pharmaceuticals business in its attempt to attain a leading position in the worldwide generic drug industry. Actavis now sells dantrolene and isradipine in the United States. It also markets amantadine,...

  • Mylan pays $6.6bn for Merck generics. Lim, Jeanne; Chang, Joseph // ICIS Chemical Business Americas;5/21/2007, Vol. 271 Issue 20, p5 

    The article reports on the plan by U.S.-based Mylan Laboratories to acquire the generics unit of Merck KGaA in Germany. Mylan has agreed to acquire Merck Generics for €4.9 billion ($6.6 billion). The combination of Mylan and Merck Generics is expected to generate revenues of about $4.2...

  • pharmaceuticals & fine chemicals.  // Chemical Week;10/26/2005, Vol. 167 Issue 35, p34 

    Presents an update on the pharmaceutical industry as of October 26, 2005. Purchase of the generic drugs operations of Alpharma by generic drugs firm Actavis Group; Decision of biotechnology manufacturer Progenitor Cell Therapy to manufacture Cellerant Therapeutics' stem cell drug candidate CLT-001.

  • Actavis to Build Three Plants in India; Opens Laboratories. Ramesh, Deepti // Chemical Week;11/3/2008, Vol. 170 Issue 34, p31 

    The article reports on the announcement by generics pharmaceutical manufacturer Actavis that it is building three pharmaceutical plants in India. It broke ground on a pilot plant and an active pharmaceutical ingredient (API) plant at the company's existing API facility at Alathur, in southern...

  • Actavis acquires bulk drugs unit of Sanmar Speciality.  // Chemical Business;Mar2007, Vol. 21 Issue 3, p78 

    The article reports that Actavis has taken over the bulk drugs division of Chennai, India-based Sanmar Specialty Chemicals Ltd. In December 2006, Actavis had taken over Gradix Pharmaceuticals, a tablets manufacturer also in Chennai. With the acquisition of Sanmar, Actavis had not only captured...

  • Actavis Expands into New Markets; May Enter Biosimilars. Ramesh, Deepti // Chemical Week;10/26/2009, Vol. 171 Issue 26, p31 

    The article reports on the decision of generic pharmaceuticals producer Actavis to expand its operations in other regions. According to Stefan Sveinsson, executive vice president of Actavis, the company is planning to enter the biosimilars market through joint ventures and partnerships....

  • Fast-rising generics producer breaks ice in the US via merger. Jarvis, Lisa // Chemical Market Reporter;5/30/2005, Vol. 267 Issue 22, p35 

    Reports that Actavis Group based in Reykjavik, Iceland, has improved its financial performance by making good on a long-standing goal of penetrating the U.S. market in the generic pharmaceuticals arena. Total revenue of the company in 2004; Number of products sold in the U.S. market for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics